eTheRNA initiates Phase Ib trial of TriMix-MEL for metastatic melanoma

Belgium-based cancer therapies developer eTheRNA Immunotherapies has initiated a Phase Ib clinical trial of TriMix-MEL (ECI-006) to treat patients with metastatic melanoma.

Source: Drug Development Technology - July 2, 2017 Category: Pharmaceuticals Source Type: news